SCHEMBL6385223

SCHEMBL6385223

O=C(OCc1cccs1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.54
THRB P10828 1/20 0.51
ALDH1A1 P00352 4/20 0.48
POLB P06746 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 2/20 0.48
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 3/20 0.46
BCL9 O00512 1/20 0.45
CTNNB1 P35222 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8808301 0.80 MAPT (0.57) THRBALDH1A1POLBSMN1; SMN2GAA
SCHEMBL272963 0.80 HTR2A (0.52) HTR2AALDH1A1SMN1; SMN2GAALMNA
SCHEMBL5827968 0.79 HTR2A (0.80) HTR2AALDH1A1GAARAB9ABCL9
Hydrochloric Acid SCHEMBL271240 0.79 HTR2A (0.51) HTR2AALDH1A1SMN1; SMN2GAALMNA
SCHEMBL1558202 0.78 THRB (0.67) THRBALDH1A1POLBSMN1; SMN2GAA
SCHEMBL6121882 0.78 GAA (0.52) THRBALDH1A1POLBSMN1; SMN2GAA
SCHEMBL7092278 0.78 HTR2A (0.53) HTR2AALDH1A1SMN1; SMN2GAALMNA
SCHEMBL1714950 0.78 HTR2A (0.70) HTR2AALDH1A1SMN1; SMN2LMNARAB9A
SCHEMBL6648115 0.77 PTPN7 (0.57) HTR2ATHRBALDH1A1POLBSMN1; SMN2
SCHEMBL24439593 0.77 HTR2A (0.52) HTR2AALDH1A1SMN1; SMN2GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1294679-B1 BETA-AMINO ACID NITRILE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-09-21 EP disclosed
EP-1294679-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-03-26 EP disclosed
US-6462076-B2 CYSTEINE PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CYSTEINE PROTEASES, SUCH AS OSTEOPOROSIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, TUMOR METASTASIS, ANGINA PECTORIS, PLAQUE RUPTURE AND STROKE ETC. HOFFMANN-LA ROCHE INC. 2002-10-08 US disclosed
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors HOFFMANN-LA ROCHE INC. 2002-02-07 US disclosed
WO-2001096285-A1 BETA-AMINO ACID NITRILE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016361-A1 Beta-amino acid nitrile derivatives as cathepsin K inhibitors CTSK, CTSH, UACA HTR2A 4584/4885THRB 1609/4885ALDH1A1 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.